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Introduction
The saponin, astragaloside IV, a 3-O-E-D-xylopyranosyl-6-O-E-
D-glucopyranosyl cycloastragenol (1), was extracted from Radix 
astragali, the dried root of the Chinese medicinal herb Astragalus 
membranaceus (Fisch.) Bunge, Fabaceae. Pharmacological studies 
indicate that astragaloside IV possesses antihypertensive, positive 
inotropic, anti-inflammatory, antinociceptive, hepatoprotective, 
neuroprotective, anti-infarction, and antiviral activities, and may 
be effective in treating viral myocarditis. In addition, astragaloside 
IV has been shown to increase T, and B lymphocyte proliferation 
and antibody production in vivo, and inhibits the production of 
IL-1 and TNF-alpha from peritoneal macrophages in vitro (Duan 
and Sun, 2011). Astragaloside IV is increasingly being explored 
as an active ingredient in therapeutics; thus, there is a need to 
develop an effective method for its quantitation in pharmaceutical 
samples. Analytical methods currently used for astragaloside 
IV detection, include high performance liquid chromatography 
(HPLC), thin-layer chromatography scanning (TLCS), and 
fluorescence methods (Ouyang et al., 2009). However, these 
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A B S T R A C T
The objective of this study was to produce artificial antigens for astragaloside IV that could 
be used to prepare antibodies against astragaloside IV screened in Radix astragali (Astragalus 
membranaceus (Fisch) Bunge, Fabaceae) and its preparations, using an indirect ELISA. 
Astragaloside IV was coupled to carrier proteins, bovine serum albumin and ovalbumin using 
the sodium periodate method and was then evaluated using SDS-PAGE, MALDI-TOF MS and 
animal immunizations. The coupling ratio of astragaloside IV to bovine serum albumin ratio 
was determined to be thirteen, and the indirect ELISA demonstrated that three groups of 
mice immunized with astragaloside IV-bovine serum albumin produced anti-astragaloside 
IV- bovine serum albumin-specific antibody, with a minimum serum titer of 1:9600. A method 
for synthesizing highly immunogenic astragaloside IV artificial antigens was successfully 
developed thus indicating its feasibility in the establishment of a fast immunoassay for 
astragaloside IV content determination in Radix astragali and its products.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
 Sheng-lan Yu et al. / Rev Bras Farmacogn 24(2014): 282-287 283
methods are complicated, mute sensitivity, require expensive 
instrumentation and are time-consuming. Immunoassays offer 
a simple, rapid, and cost-effective alternative to the traditional 
methods listed above, particularly when high efficiency and 
on-site screening tests are required. The successful preparation 
of artificial antigens is the first critical step in establishing any 
immunoassay method. Antigens (haptens) with a molecular 
weight (MW) less than 1000 are generally not immunogenic, and 
require conjugation with a carrier protein to elicit an immune 
response. Astragaloside IV is a relatively small molecule, 
with a molecular weight of 784; thus, it is not immunogenic; 
failing to elicit an immune response because it lacks epitopes 
recognized by T cells to stimulate antibody production. However, 
astragaloside IV, like other haptens can be chemically modified at 
an appropriate position to introduce a spacer with an active group 
at the end. The modified hapten is coupled to a macromolecular 
carrier to form a hapten-carrier conjugate (e.g. artificial antigen). 
The artificial antigen can make use of T cell epitopes to indirectly 
induce B cell proliferation and differentiation to generate specific 
antibodies against small molecular compounds (Jiao et al., 2004).
Biological Technology Co., Ltd. Bovine serum albumin (BSA), 
ovalbumin (OVA), Freund’s complete adjuvant (FCA) and 
Freund’s incomplete adjuvant (FICA) were purchased from 
Sigma-Aldrich. The animal experimentation protocols were 
approved by the Animal Care and Use Committee of Yangzhou 
University, and all experiments were conducted according to 
the guidelines of Yangzhou University (Institutional Ethical 
Committee Number SCXK (su) 2009-0002). Female Balb/C mice 
(6-7 weeks old) were purchased from the Laboratory Animal 
Service Center of the Yangzhou University (China). The mice 
were kept in an animal facility in controlled conditions, 
temperature at 22 ± 2°C and relative humidity of 50 ± 10%. 
Food and water were available ad libitum. 
Preparation of AST-carrier protein conjugates
AST-BSA and AST-OVA were prepared by the sodium periodate 
method (Zhao et al., 2007). Briefly, 1 ml of AST in methanol 
(10 mg/ml) was added by dripping to 0.06 M NaIO4, stirring 
at room temperature. After 1 h, BSA (35.7 mg BSA in 10 ml 
carbonate buffer, pH 9.6) was slowly added during stirring, 
and the reaction incubated for 6 h at room temperature. The 
conjugates were lyophilized following dialysis against distilled 
water for three days at 4°C, and stored at -20°C. AST-OVA were 
prepared as for AST-BSA. Scheme 1 illustrates the synthesis of 
the hapten derivatives for AST.
Scheme 1 – Synthesis of hapten derivatives for astragaloside 
IV (R).
 
In the present study, astragaloside IV was coupled to BSA 
to synthesize the artificial antigen, AST-BSA. The formation 
of AST-BSA was confirmed by SDS-PAGE and MALDI-TOF MS. 
An indirect ELISA was used for specificity analysis and for 
the determination of anti-AST-BSA specific antibody titers in 
serum. The results of this study laid the foundation for the 
preparation of monoclonal antibodies against astragaloside IV, 
and for the rapid detection of astragaloside IV in Radix astragali 
and its preparations using indirect ELISA.
Materials and methods
Reagents and animals
Astragaloside IV standards (AST) were purchased from 
Chengdu Mansite Bio-Technology Co., Ltd. TMB was purchased 
from Solarbio Co., Ltd. Horseradish peroxidase HRP-conjugated 
goat anti-mouse IgG was purchased from Wuhan Boster 
Analysis of AST-carrier protein conjugates by polyacrylamide 
gel electrophoresis
Conjugates were analyzed under denaturing conditions by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
using an adaptation of the method of Joseph and David (2001). 
Briefly, 20 μl of conjugate (0.5 g/l) was mixed with an equal volume 
of 2×SDS protein loading buffer (1M Tris-HCl; pH 6.8, 2% (w/v) 
SDS, 5% (v/v) E-mercaptoethanol, 10% (v/v) glycerol, and 0.02% 
(v/v) bromophenol blue) and let to boil for 5 min. The denatured 
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Figure 1 – The results of non-denaturing polyacrylamide gel 
electrophoresis.
Lane 1 BSA sample 2 MarkerI 3 MarkerII 4 OVA sample 5 AST-OVA 
sample 6 MarkerII 7 AST-BSA sample.
samples were fractionated by electrophoresis in a 5% (w/v) stacking 
and 15% (w/v) separating, polyacrylamide gel, with 0.1% (v/v) SDS 
in Tris-glycine as the buffer. Electrophoresis was conducted at 90 
V and 120 V in the stacking and separating gels, respectively, and 
ceased once the dye reached the end of the gel. Coomassie brilliant 
blue R-250 solution (0.1% (w/v) in 25% (v/v) isopropyl alcohol and 
10% (v/v) acetic acid) were used as gel staining agents for more than 
4 h at room temperature, with gentle shaking (Kong et al., 2010). 
The gels were destained (50% (v/v) methanol, 10% (v/v) acetic acid) 
three to four times until the bands were clearly resolved. Images 
of the gels were taken using a UVI gel auto imaging system (Tanon 
Science & Technology Co., Ltd.).
Determination of the hapten/carrier protein ratio of AST-BSA 
by MALDI-TOF MS
Trifluoroacetic acid (TFA) 5% (30 μl) was added to 17 μl acetonitrile, 
then erucic acid added until the solution reached oversaturation, 
ultrasonicated for 15 min, and centrifuged at 112 g for 3 min.  The 
solution was stored at 4°C. The AST-BSA solution (1 μl) (0.6 mg 
AST-BSA in 30 μl 8 mol/l urea solution diluted to the appropriate 
concentration, 1 mg BSA in 50 μl water) was mixed with matrix-
assisted solution as the original sample. The plate was spotted 
with 1 μl of the original sample, point to the standard adjacent 
target and left to dry, and spotted 0.6 nl SA matrix, after drying, to 
be analyzed by MALDI TOF MS Spectrometer (AB 4800, USA). The 
hapten/carrier protein ratio of AST-BSA could be calculated by their 
respective molecular weights according to the following formula:
Conjugate proportion = (MrAST-BSA- MrBSA)/MrAST (Yang et al., 
2010)
Animal immunizations
Twenty five Balb/C mice (6 weeks old) were randomly divided into 
five groups with five mice in each group. Three groups (Groups 1, 
2, and 3) were immunized with differing amounts of AST-BSA; 
administered four times over a period of 45 days. The mice were 
injected subcutaneously with 0.2 ml (Group 1), 0.4 ml (Group 2) and 
0.6 ml (Group 3) AST-BSA mixed with FCA (1:1 antigen/adjuvant) 
on day 1. On day 15 they were administered the same volume of 
AST-BSA combined with FICA (1:1 antigen/adjuvant). On days 30 
and 45, the mice were administered the same volume of AST-BSA 
alone (Boesen et al., 2005). The fourth group (negative control) was 
immunized with BSA as per the experimental groups, and the fifth 
group (blank control) was left untreated. Three days after the last 
injection the mice were bled from the eye and the serum antibody 
titers determined using an indirect ELISA (Shin et al., 2006).
Indirect ELISA for the detection of anti-AST-BSA antibodies
The indirect ELISA was conducted in Corning 96 well microtiter 
plates (Corning, NY) coated with 1.25 μg/mg AST-OVA in 50 mM 
carbonate buffer (pH 9.6) and incubated overnight at 4°C. The 
plates were washed three times with 0.05% Tween 20 in PBS 
(PBST) and non-specific protein binding sites were blocked with 
1% (w/v) skim milk powder in PBS at 37°C for 1 h. Serum obtained 
from the three groups of mice immunized with AST-BSA, the 
negative control group (saline) and blank control (normal mouse 
serum) were diluted 1:1000 to 1:32000 in PBS, and 100 μl added 
to the wells of the plate, tests were performed in triplicate. The 
plates were incubated for 60 min at 37°C, washed with PBST, and 
a 1:5000 dilution of HRP-conjugated goat anti-mouse IgG in PBS 
added to each well. The plates were incubated for 60 min. at 37°C, 
washed, and TMB substrate solution (0.2 mg/ml TMB and 50 μl 
30% H2O2, in 10 ml 0.1M citrate-0.2M phosphate buffer, pH 5.2) 
added. The plates were incubated for 30 min at room temperature 
and the reaction stopped with 50 μl 2M H2SO4. The optical density 
was measured at a wavelength of 450 nm using the BioTek ELx800 
ELISA reader (Wei et al., 2012). Each sample was replicated three 
and the average value was used as the final value.
Results and discussion
Analysis of AST-carrier protein conjugates by SDS-PAGE.  
Proper hapten design was essential for antibody production and 
ELISA development. AST is a small molecular compound (MW of 
784 kDa), and as such is not immunogenic. In order for AST (and 
other haptens) to elicit an immune response it must be conjugated 
to a carrier protein. The haptens must contain functional groups, 
or be easily derivatized, to incorporate reactive groups (such as 
amino, carboxyl, diazo group) for cross-linking reactions with 
the protein (Song et al., 2010). The carboxyl and hydroxyl groups 
on hydroxylated haptens must be activated for cross-linking 
with carrier proteins. AST is polyhydroxy and consequently 
the first reaction with sodium periodate is the oxidation of the 
polyhydroxy group to react to aldehyde and carboxyl groups, 
which conjugate with the amino group of BSA through an amide 
bond, to generate the AST-BSA protein complex. Normally, UV 
spectroscopy is used to identify if the hapten has been conjugated 
to the carrier protein, however, AST has no absorption in the 
ultraviolet region, thus, and in the current study we used protein 
electrophoresis to evaluate the successful coupling of AST to the 
carrier protein BSA preliminarily.
The results of the SDS-PAGE analysis of AST-BSA and 
AST-OVA conjugates are presented in Fig. 1. As shown, the 
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binding ratio of 13.4 established in the current study suggests 
that coupling conditions used for the hapten and the carrier 
successfully generate a strong immunogen.
Determination of serum anti-AST-BSA-specific antibody titers
The optimum concentrations of antigen were determined 
and the serum anti-AST-BSA-specific antibody titers of 
mice immunized with AST-BSA conjugates were measured 
using an indirect ELISA to confirm the AST-BSA conjugate 
has a strong immunogenicity. As the mice were immunized 
with AST-BSA when performing an indirect ELISA, AST-
OVA were selected to coat the plate in order to avoid the 
effect of the antibody in the serum capable to conjugate with 
BSA. BSA is very immunogenic and it will be able to present 
a large number of cross-reactions so the serum from mice 
immunized with BSA was selected as a negative control in 
order to avoid a false positive reaction. The optical density 
(OD) for the control serum was significantly lower than the 
OD for test serum (p < 0.05). Final values are presented as 
the average of three replicates ± the standard deviation. 
The titers of anti-sera for groups 3 (immunized with 0.6 ml 
AST-BSA per time), 2 (immunized with 0.4 ml AST-BSA per 
time), and 1 (immunized with 0.2 ml AST-BSA per time) were 
25,600, 12,800 and 9,600, respectively (Fig. 4). These results 
demonstrate that the conjugates had good immunogenicity. It 
can then be concluded that immunization of Balb/C mice with 
artificial antigen produced high anti-AST-BSA-specific serum 
titers, as measured by the indirect ELISA. This experiment 
lays the foundation to assay AST using an indirect ELISA 
approach.
electrophoretic migration pattern of the AST-carrier proteins, 
AST-BSA and AST-OVA, differ from their respective carrier 
proteins, OVA and BSA. As expected, the electrophoretic 
mobility of BSA was greater than that of AST-BSA, and 
similarly, greater for OVA than that for AST-OVA. These results 
are consistent with the greater molecular weights of AST-BSA 
and AST-OVA compared with BSA and OVA, respectively. 
These results demonstrate the artificial antigens, AST-BSA 
and AST-OVA, were produced successfully.
Determination of the hapten/carrier protein ratio of AST-BSA 
by MALDI TOF MS
As the titer of antibody serum is often affected by the ratio of 
hapten/carrier, it was necessary to detect the ratio of hapten/
carrier before immunizing the mice. Hapten ratios for the 
conjugates could not be measured by UV spectroscopy by 
the reason above-mentioned that AST has no absorption in 
the ultraviolet region, so the prepared AST-BSA conjugate 
product was examined by MALDI TOF MS to detect the hapten/
carrier protein ratio. The identification of BSA and AST-BSA 
conjugates by MALDI TOF MS are presented in Fig. 2 and Fig. 3, 
respectively. The molecular weight of BSA was determined 
as 66,446.4766 kDa (Fig. 2) and the molecular weight of the 
AST-BSA conjugate as 76,970.9609 (Fig. 3). The hapten/
carrier protein ratio was determined as 13.4 by the formula: 
Conjugate proportion = (MrAST-BSA- MrBSA)/MrAST) [(76970.9609-
66446.4766)/66446.4766≈13.4:1]. Accordingly, the hapten/carrier 
protein ratio is approximately 13:1. According to the literature, 
hapten/carrier ratios of 3:1-45:1 indicate artificial antigens with 
strong immunogenicity (Wang et al., 2011). So the AST-BSA 
Figure 2 – Identification of BSA by MALDI-TOF MS.
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Figure 3 – Identification of astragaloside IV-BSA by MALDI-TOF MS.
Figure 4 – Serum anti-AST-BSA antibody titers from immunized mice.
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